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Glucagon was tested for its effect on plasma adenosine 3',5'-cyclic monophosphate 
(cyclic AMP), insulin, and glucose in healthy subjects and in patients with advanced 
cirrhosis of the liver. In the normal subjects, intravenous infusion of glucagon caused a 
significant increase in plasma cyclic AMP, glucose, and insulin. In advanced cirrhotics, 
plasma cyclic AMP, glucose, and insulin did not increase. Adenylate cyclase concentra-
tion was measured in liver tissue from end stage cirrhotic patients and from brain-dead 
organ donors whose cardiovascular function was maintained in a stable state. Basal 
and total adenylate cyclase concentration were not different in the two groups. 
Adenylate cyclase from the livers of advanced cirrhotics was, however, significantly 
less responsive to glucagon stimulation than was that from donor livers. Hepatocytes in 
advanced cirrhosis have abnormal metabolic behavior characterized by abnormal 
adenylate cyclase-cyclic AMP response to hormonal stimulation. 
Intracellular effects mediated by adenosine 3' ,5'-
cyclic monophosphate (cyclic AMP) have been described 
after interaction of many hormones with their target 
tissues. I Several studies have shown that cyclic AMP 
can pass from the intracellular compartment into 
plasma2-4 and that the rate of this passage can be 
altered by changes in plasma concentrations of certain 
hormones.'>-8 Changes in rate of cyclic AMP passage 
might be attributable to changes in intracellular nu-
cleotide concentration or in cell membrane permeabil-
ity.9 
Intravenous infusion of glucagon into normal humans 
has been shown to increase plasma and urine concentra-
tions of cyclic AMP. 10 Liljenquist et al. have indicated 
that the liver is an important source of circulating cyclic 
AMP in man, and that glucagon increases the release of 
this nucleotide into the hepatic vein. II Recent studies 
by Strange and Mj0s on functionally hepatectomized 
rats have shown that the liver is the main source of 
glucagon-stimulated increase in plasma cyclic AMP.12 
Confirmatory data from rabbits have been reported by 
J erums et al. I:J 
Because cyclic AMP is known to stimulate glycogen-
olysis, gluconeogenesis, and lipolysis in the hepatic 
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cell,I4-17 the "glucagon test" measuring blood-glucose 
response to glucagon injection has been proposed as an 
index of liver function. 18-20 Results have been contradic-
tory, however, in large part because glucose metabolism 
in cirrhosis is affected by many factors. 21-26 
We have remained convinced that changes in plasma 
cyclic AMP levels in response to glucagon infusion may 
be of great potential interest as a test of the metabolic 
status and/or functional capability of hepatic cells. 
However, recent reports27,28 have not agreed on the 
effects of glucagon infusion in cirrhotic patients. The 
present study was undertaken to examine the effects of 
exogenous glucagon infusion on plasma cyclic AMP and 
liver adenylate cyclase concentration and on insulin 
and glucose levels in control subjects and in patients 
with decompensated liver cirrhosis. 
Because hyperglucagonemia has been demonstrated 
in cirrhotic patients29, 30 and has been shown to affect 
responsiveness of adenylate cyclase to glucagon stimu-
lation,31-34 we have also felt that studying hepatic aden-
ylate cyclase concentration in this situation was impor-
tant. 
Patients and Methods 
Informed consent was obtained from all subjects before 
inclusion in the study. 
Subjects 
Glucagon infusion tests were performed on 9 healthy adult 
subjects and on 11 patients with advanced liver cirrhosis. The 
diagnosis of liver cirrhosis was made on clinical grounds and 
supported by liver function tests and liver biopsy. 
A complete liver profile including determination of serum 
bilirubin, alkaline phosphatase, SGOT, SGPT, serum choles-
1026 
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terol, serum total protein and protein electrophoresis, blood 
ammonia and serum bromsulphalein retention, and prothrom-
bin time was carried out in all patients before glucagon 
infusion. Liver function tests in these cirrhotic patients are 
listed in table 1. All control patients had liver profiles within 
the normal range. 
Liver biopsy was done in cirrhotics a few minutes before the 
infusion test whenever possible (prothrombin time up to 18 
sec with control of 12 sec). In any case, all cirrhotic patients 
had liver biopsies confirming cirrhosis at some time before 
inclusion in the study. Both ascites and esophageal varices 
demonstrated by barium esophagogram were present in all 
advanced cirrhotics none of whom had undergone gastric or 
portal surgery. 
In addition, adenylate cyclase concentration was deter-
mined on liver tissue from 9 more patients with advanced 
cirrhosis at the time of liver transplantation. Liver profiles 
from these patients are shown in table 1. Cirrhotic liver 
adenylate cyclase was compared with liver adenylate cyclase 
concentration from 5 previously healthy brain-dead organ 
donors with stable cardiovascular function. 
Experimental Procedures 
Glucagon infusion tests were performed after an overnight 
fast. All patients had peripheral venous catheters placed and 
0.9% saline infused. Control venous blood samples for plasma 
cyclic AMP, insulin, and glucose were drawn with heparinized 
syringes 20 and 10 min before glucagon infusion. A solution of 
glucagon (synthesized by Nova Industrials Laboratory, Den-
mark) in 0.9% saline was substituted for the saline and 
infusion continued at a rate of 200 ng of glucagon per kg per 
min by means of a Dascon infusion pump (BV Dascon, Uden, 
Netherlands). Peripheral venous blood samples were obtained 
with heparinized syringes at lO-min intervals for 60 min. 
Plasma was immediately separated by centrifugation (3 to 
5°C) and stored at - 20°C until analysis. 
Liver taken from cirrhotic patients before liver transplan-
tation and from brain-dead donors was immediately cooled in 
ice-cold saline and assayed. 
Analytical Procedures 
Cyclic AMP. Cyclic AMP was determined by the protein 
binding assay of Gilman.35 Cyclic AMP-dependent protein 
kinase was purified from 500 g of sirloin tip steak by the 
method of Miyamoto et al. 36 Protein kinase inhibitor prepara-
tion was carried out according to Walsh et alY Nonradioactive 
cyclic AMP was obtained from Sigma Chemical Company (St. 
Louis, Mo.), tritiated l8-3Hladenosine 3' ,5 '-cyclic monophos-
phate with specific activity of 28 Ci/m mol from Schwarz/ 
Mann, Inc. (Orangeburg, N. Y.), and cellulose ester filters 
(HA 0.45 mm) from Millipore Corporation (Bedford, Mass.). 
After deproteinization with ethanol, plasma samples for 
cyclic AMP assay were centrifuged and the supernatant evap-
orated to dryness under nitrogen stream at 55°C. The residue 
was then dissolved in 0.5 ml of 0.2% sodium acetate buffer (pH 
4.0) and reaction was conducted in a volume of 250 /-tl. Cyclic 
nucleotide was subsequently measured and corrected for the 
recovery of [3Hlcyclic AMP. To confirm that cyclic AMP had 
been measured, the samples were treated with cyclic AMP-
phosphodiesterase as described by Brooker et al,'l8 No cyclic 
AMP could be detected after this treatment. 
Plasma insulin was determined by radioimmunoassay us-
ing the insulin kit from CIS (Sorin, Saluggia based on the 
method ofYalow and Berson39). 
Glucose. Plasma glucose was determined with a commercial 
glucose oxidase preparation (Biochemic a Test Combination, 
Boehringer Mannheim GmbH, Mannheim, West Germany). 
All plasma samples were measured in duplicate. 
Adenylate cyclase. Homogenate from human livers was 
prepared immediately after biopsy, according to the method of 
Makman and Sutherland.40 Small pieces of liver were forced 
through a fine mesh metal sieve with a hand-operated flut 
plunger before homogenization with a Potter-Elvehjem ho-
mogenizer. The homogenate was then rapidly frozen in liquid 
nitrogen and stored until use. 
Basal, glucagon-stimulated, and fluoride-stimulated aden-
ylate cyclase concentrations were determined by the method 
of Salomon et al. 41 based on a combination of chromatography 
TABLE 1. Liver function tests in cirrhotic patients 
Group Total Albumin y-Globulin Serum Blood BSpa SGOT SGPT Alkaline Total PT" protein cholesterol ammonia retention phosphatase bilirubin 
U g/lOO ml % % mg/lOO ml l'lJ/lOO ml % mU/ml IV mg/lOO ml sec 
Normal 6.6-8.7 55-68 14-19 150-250 21-86 <4.7 <12 <12 25-92 <1.0 <12.0 
Glucagon infusion 1 5.4 41 40 100 150 18 20 15 35 1.53 14 
test subjects 2 6.0 45 43 130 240 43 18 15 170 1.26 16 
3 5.1 38 47 40 160 40 22 10 608 6.40 21 
4 5.0 40 50 130 300 68 25 12 325 1.00 18 
5 5.6 45 32 120 350 32 32 13 424 8.60 20 
6 4.6 44 38 83 180 42 57 59 191 1.05 23 
7 5.0 47 42 103 220 38 21 5 56 2.76 16 
8 5.2 50 30 100 160 41 30 10 74 18.70 19 
9 6.0 35 47 98 200 20 92 77 134 7.00 14 
10 5.4 48 30 105 160 25 80 74 105 6.50 15 
11 6.1 45 35 90 140 30 50 40 80 2.50 18 
Liver adenylate cy- 1 6.0 30 273 132 274 13 14 
clase subjects 2 7.1 41 93 60 1270 7 12 
3 6.8 51 92 51 450 6.9 11 
4 3.9 142 375 572 2.5 14.5 
5 5.2 35 208 134 390 18 15 
6 5.3 43 335 155 726 21 12 
7 6.1 43 39 59 41 39 21 
8 5 50 17 15 116 1.5 13 
9 7.5 60 334 215 2055 22.8 15 
a BSP, bromsulphalein. 
b PT, prothrombin time. 
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on both Dowexcation exchange resin according to Krishna et 
al.42 and aluminum oxide according to White and Zenser''' as 
previously described.44 
Statistical procedures. The mean of values obtained at 10 
and 20 min before glucagon infusion was considered as the 
control value for plasma cyclic AMP, insulin, and glucose. 
All results have been expressed as mean ± SEM. Differences 
between values were tested for significance by Student's t-
test. 
Results 
Glucagon infusion tests. Table 2 shows plasma cyclic 
AMP concentration in healthy subjects and cirrhotic 
patients during infusion of 0.9% saline at 20 and 10 min 
before glucagon infusion. In healthy subjects, plasma 
cyclic AMP rose promptly and remained significantly 
elevated throughout the glucagon infusion test. In con-
trast, cyclic AMP failed to rise in advanced cirrhotics 
(fig. 1). 
In healthy subjects, insulin concentrations rose sig-
nificantly and remained elevated throughout the gluca-
gon infusion test. In cirrhotics, only minimal insignifi-
cant increases occurred (fig. 2). 
TABLE 2. Basal plasma cyclic AMP in healthy subjects and in 
patients with advanced cirrhosis 
Healthy subjects (n = 9) 
Range 
Mean 
±SEM 
Cirrhotic patients (n = 11) 
Range 
Mean 
+SEM 
Q Time before glucagon infusion. 
Saline infusion 
20 mina 
6-23 
13.55 
1.84 
6-18 
12.54 
1.31 
1000 ~ 
800 
BOO 
700 
pmolelml 
10 min" 
0-25 
15.88 
2.34 
7-16 
11.81 
1.06 
Plasma glucose levels also rose rapidly and signifi-
cantly in healthy subjects. Although base-line plasma 
glucose levels were significantly higher in cirrhotics 
than in healthy subjects, plasma glucose did not in-
crease in response to glucagon infusion in these patients 
(fig. 3). 
Hepatic adenylate cyclase concentration. Basal, glu-
cagon-stimulated, and sodium fluoride-stimulated ac-
tivities from donor livers are reported in table 3. Gluca-
gon-stimulated activities increased steadily with in-
creasing glucagon concentrations until near total (so-
dium fluoride-stimulated) activity was achieved at glu-
cagon concentration of 10 -5 M. 
Adenylate cyclase concentrations from end stage cir-
rhotic livers were more heterogeneous (table 3). Al-
though basal and total concentrations did not differ 
significantly from those of donor livers, they seemed to 
fall into high activity and low activity groups. In these 
cirrhotic livers, glucagon-stimulated concentrati~ns 
rose less rapidly and to significantly lower levels WIth 
increasing glucagon concentration. Near total stimula-
tion was never achieved with glucagon stimulation. 
Discussion 
Our results indicate that intravenous glucagon infu-
sion causes different responses in healthy subjects and 
in patients with advanced cirrhosi~K f~ normal s.ubjects, 
glucagon infusion caused a rapId mcrease m both 
plasma cyclic AMP levels and pl~sma glucose. These 
increases were expected because It has been demon-
strated that the effect of glucagon on the liver depends 
on an adenylate cyclase-mediated increase in cyclic 
AMP.'4---'7 Both plasma cyclic AMP and plasma glucose 
then plateaued with continued infusion of glucagon. 
Plasma insulin had substantially increased by that 
time. The effects on insulin have been attributed. to 
glucagon administration,45 hyperglycemia,46--48 and m-
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FIG. 1. Plasma cyclic AMP concentration in 9 control subjects and in 11 cirrhotic patients at various intervals during gluc~gon infusio~K 
Values are mean ± SEM and show the probability that concentrations during fasting do not differ from those at zero hme (paIred Student s 
t-test); n.s., not significant. 
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FIG. 2. Plasma insulin concentration in 9 control subjects and in 11 cirrhotic patients at various intervals during glucagon infusion. 
Values are mean ± SEM and show the probability that concentrations during fasting do not differ from those at zero time (paired Student's 
t-test); n.s., not significant. 
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FIG. 3. Plasma glucose concentration in 9 control subjects and 11 cirrhotic patients at various intervals during glucagon infusion. Values 
are mean ± SEM and show the probability that concentrations during fasting do not differ from those at zero time (paired Student's t-test); 
n.s., not significant. 
creases in circulating cyclic AMP. 4!>-53 The increase in 
insulin levels could account for the transient nature of 
the glucagon mediated effect because insulin has been 
demonstrated to decrease hepatic cyclic AMP and the 
glycogenolytic and gluconeogenic effect of cyclic AMP. 
This antagonism between insulin and glucagon repre-
sents one of the most important factors controlling liver 
metabolism.54-57 Wahren et al. have demonstrated, how-
ever, that the effect of glucagon on splanchnic glucose 
production is evanescent even in the face of absolute 
insulin deficiency. 58 
On the other hand, plasma cyclic AMP, glucose, and 
insulin all failed to respond to glucagon infusion in the 
patients with advanced cirrhosis. This unresponsive-
ness might be attributed to several factors. Glucagon 
might bypass the liver by way of portal systemic shunts 
because all of these patients had demonstrated esopha-
geal varices. This is probably not of major importance 
in our stud!es because infusion times were long and 
hormone dose,' high. Impaired responsiveness of hepatic 
adenyl ate cycla3e h<>.:: been demonstrated in hyperglu-
cagonemic states from either endogenous or exogenous 
glucagon.31-34 We have demonstrated decreased respon-
siveness of hepatic adenyl ate cyclase to glucagon stim-
ulation in our group of end stage cirrhotic patients 
submitted to liver transplantation. Although basal and 
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TABLE 3. Adenylate cyclase concentration in donor and end stage cirrhotic livers (nanomoles cyclic AMP/mg protein homogenate/I5 min) a 
Glucagon stimulated NaF 
No. Diagnosis Age Basal H2O stimulated 
10-· 10-8 10-7 10-6 10-5 (10 mM) 
yr 
Donor 
1 50.8 132 167 234 226 269 273 
2 80.7 109 121 161 218 331 336 
3 80 105 152 232 293 329 304 
4 65 87 124 203 212 248 289 
5 51 64 77.4 109 148 129 209 
Mean ± SD 65.5 ± 14.7 99.3 ± 22.5 132 ± 30.8 188 ± 47.7 230 ± 55.8 270 ± 59.1 282 ± 47 
Cirrhotic 
1 Biliary atresia 10mo 49.1 49.5 51.5 54.0 54.0 59.4 201 
2 Arteriovenous 51 41.2 62.2 66.3 72.9 82.4 76.2 135 
malformation 
3 Biliary atresia 11 37.1 47.7 54.5 60.4 59.3 61.2 154 
4 aI-Antitrypsin 51/2 43.8 61.7 74.0 91.5 99.4 112 197 
deficiency 
5 Biliary atresia 31/2 165 184 219 287 288 282 519 
6 Chronic aggres- 14 94 98 125 198 212 207 441 
sive hepatitis 
7 Alcoholic cirrhosis 35 55 55 97 95.7 113 128 200 
8 Alcoholic cirrhosis 46 162 164 168 202 194 185 583 
9 Biliary atresia 13 mo 57.9 67 66 84.5 90.8 109 215 
Mean ± SD 75 ± 47 90 ± 50 102 ± 54.5 127 ± 76 133 ± 26 136 ± 70 306 ± 167 
P" NS' NS NS NS <0.02 <0.01 NS 
a Basal activity reflects receptor and catalytic components of adenylate cyclase concentration; glucagon-stimulated values reflect receptor 
activity at different molar concentrations of glucagon; sodium fluoride (NaF)-stimulated values reflect the full (catalytic) concentration of 
adenylate cyclase. 
b Compared to donor liver by Student's t-test. 
, NS, not significant. 
total adenylate cyclase concentrations were not differ-
ent from those determined for nondiseased donor livers, 
glucagon stimulation was much less effective and failed 
to approach maximal response in the livers from these 
end stage cirrhotic and, no doubt, hyperglucagonemic 
patients. The mechanism for this impairment is specu-
lative. Srikant et al. have recently demonstrated a 
reduction in glucagon-binding sites in livers of rats 
made chronically hyperglucagonemic.59 Rather surpris-
ingly, these investigators were unable to show a corre-
lation between terminal plasma glucagon concentration 
and the reduction in receptor concentrations. In their 
hyperglucagonemic models, the ability of glucagon to 
stimulate adenylate cyclase was not reduced proportion-
ately by the reduction of glucagon-binding sites. 
We can only speculate on why our patients with 
cirrhosis responded significantly differently to glucagon 
infusion from those reported by Strange et al., 28 who 
found no significant difference in cyclic AMP or glucose 
response between cirrhotics and controls. We employed 
higher doses of glucagon and achieved much higher 
plasma cyclic AMP levels in our normal controls. A 
more likely explanation is that our patients had more 
heterogeneous cirrhosis than did their generally well 
compensated patients. Our patients, with demonstrated 
spontaneous portal systemic shunting, responded much 
more like the cirrhotics who had undergone shunt 
surgery reported by Davies et al. 27 Our results suggest 
that hepatocytes from patients with advanced cirrhosis 
have abnormal metabolic behavior or, more specifically, 
an abnormal adenyl ate cyclase system. This unrespon-
siveness to known hepatotrophic factors57 could further 
damage the already injured liver. 
These findings suggest new prospects for the glucagon 
infusion test in determining the degree of parenchymal 
dysfunction in patients with liver disease and cirrhosis. 
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